ABCL · AbCellera Biologics Inc.
$11.82
+3.96% last session
End-of-day data · close of 2026-10-23
Market cap
$4B
Enterprise value
$3B
Trailing P/E
—
Forward P/E
-15.5
Dividend yield
0.0%
Beta
1.41
Avg volume
7M
Employees
1K
Daily Change %
3.96%
5 Days Change
-0.92%
10 Days Change
-4.45%
30 Days Change
-6.56%
60 Days Change
-5.44%
Month to Day Change
-15.03%
Year to Day Change
245.61%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — ABCL
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-10-12
Latest call per bank · past 12 months
UBS
Buy$18.00
+52.3% vs priceJP Morgan
Overweight$17.00
+43.8% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-12 | UBS | Initiates | Buy | $0.00 → $18.00 |
| 2026-09-29 | JP Morgan | Initiates | Overweight | $0.00 → $17.00 |
| 2026-08-11 | Truist Securities | Maintains | Buy | $12.00 → $30.00 |
| 2026-08-06 | Stifel | Maintains | Buy | $8.00 → $9.00 |
| 2026-08-06 | Cantor Fitzgerald | Maintains | Overweight | $11.00 → $12.00 |
| 2026-07-07 | Benchmark | Upgrade | Hold → Buy | $0.00 → $11.00 |
| 2026-05-05 | Cantor Fitzgerald | Initiates | Overweight | $0.00 → $7.00 |
| 2026-04-10 | Jones Trading | Initiates | Buy | $0.00 → $11.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-10-23
- neutral: RSI (14): RSI is 46 — neutral momentum, neither overbought nor oversold.
- bearish: Price vs 50-day MA: Trading 2.7% below the 50-day MA ($12.15).
- bullish: Price vs 200-day MA: Trading 78.0% above the 200-day MA ($6.64).
- bullish: MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- bearish: MACD (12,26,9): MACD histogram is negative (-0.22) — short-term momentum is fading.
- neutral: 52-week range: Price sits between the 52-week low ($2.78) and high ($14.82).
ABCL Price Chart
Loading chart for ABCL…
Fundamentals
About AbCellera Biologics Inc.
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; AbbVie Inc.; Jazz Pharmaceuticals plc to develop T-cell engaging (TCE) multispecific antibodies; partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc.; and Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$133B 18.1% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$83B 6.5% YTD
MRNA
Moderna, Inc.
$80B 587.1% YTD
ARGX
argenx SE
$55B 4.1% YTD
ONC
BeOne Medicines Ltd.
$43B 25.8% YTD
RVMD
Revolution Medicines, Inc.
$40B 135.6% YTD
RPRX
Royalty Pharma plc
$37B 67.3% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$30B -42.8% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.